Puma Biotechnology
PBYI
116 hedge funds and large institutions have $2.49B invested in Puma Biotechnology in 2013 Q4 according to their latest regulatory filings, with 36 funds opening new positions, 37 increasing their positions, 41 reducing their positions, and 11 closing their positions.
227% more first-time investments, than exits
New positions opened: 36 | Existing positions closed: 11
200% more funds holding in top 10
Funds holding in top 10: 1 → 3 (+2)
104% more capital invested
Capital invested by funds: $1.22B → $2.49B (+$1.27B)
75% more call options, than puts
Call options by funds: $7.69M | Put options by funds: $4.39M
26% more funds holding
Funds holding: 92 → 116 (+24)
4.65% more ownership
Funds ownership: 79.19% → 83.84% (+4.7%)
10% less repeat investments, than reductions
Existing positions increased: 37 | Existing positions reduced: 41
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
T. Rowe Price Associates
Baltimore,
Maryland
|
+$93.4M |
| 2 |
Citadel Advisors
Miami,
Florida
|
+$27.3M |
| 3 |
Adage Capital Partners
Boston,
Massachusetts
|
+$26.1M |
| 4 |
CCI
Columbus Circle Investors
|
+$16.4M |
| 5 |
JHIU
Janus Henderson Investors US
Denver,
Colorado
|
+$14.1M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Fidelity Investments
Boston,
Massachusetts
|
-$42.8M |
| 2 |
Jennison Associates
New York
|
-$18.9M |
| 3 |
Wellington Management Group
Boston,
Massachusetts
|
-$17.2M |
| 4 |
TCM
Tekla Capital Management
Boston,
Massachusetts
|
-$16M |
| 5 |
Ameriprise
Minneapolis,
Minnesota
|
-$12.5M |
PBYI Hedge Fund Activity: Q4 2013 in Review
116 of the 3,459 institutional investors tracked by Wall St. Rank reported a position in Puma Biotechnology (PBYI) for Q4 2013, worth a combined $2.49B — up 104% from $1.22B a quarter earlier.
Buyers outnumbered sellers: 36 funds opened new PBYI positions and 11 closed out — a net gain of 25 holders — while 37 added to existing stakes and 41 trimmed.
The largest buyer was T. Rowe Price Associates, adding an estimated $93.4M. The largest seller was Fidelity Investments, cutting an estimated $42.8M.
- 116 institutional investors held Puma Biotechnology (PBYI) as of Q4 2013, up from 92 in Q3 2013.
- Funds reported $2.49B of Puma Biotechnology stock for Q4 2013, up 104% quarter-over-quarter.
- 36 funds opened new Puma Biotechnology positions in Q4 2013 and 11 closed out, a net change of +25 holders.
- The largest Puma Biotechnology buyer in Q4 2013 was T. Rowe Price Associates, an estimated $93.4M added.
- The largest Puma Biotechnology seller in Q4 2013 was Fidelity Investments, an estimated $42.8M sold.
Based on aggregated 13F filings for Q4 2013.